Study of ORIC-944 in Patients With Metastatic Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany rak prostaty z przerzutami
- •Usunięte jądra lub stosowanie leków obniżających testosteron
- •Wcześniejsze leczenie nowotworów (różne wymagania w zależności od części badania)
- •Potwierdzony progres choroby - wzrost poziomu PSA, nowe ogniska lub wzrost zmian
- •Zdolność do poddania się biopsji skóry i tkanki nowotworu
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Prawidłowe funkcje narządów wewnętrznych
✗ Disqualifies
- •Przerzuty do mózgu (chyba że leczone i stabilne)
- •Ciężka niewydolność serca lub poważne zaburzenia rytmu serca w ostatnich 6 miesięcy
- •Zawał mięśnia sercowego w ostatnich 6 miesięcy
- •Niestabilna lub źle kontrolowana choroba serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (27)
Rocky Mountain Cancer Center
Colorado Springs, United States
South Florida Oncology and Hematology
Plantation, United States
Illinois Cancer Specialists
Arlington Heights, United States
Comprehensive Urologic Care
Lake Barrington, United States
First Urology
Jeffersonville, United States
Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland
Baltimore, United States
Maryland Oncology Hematology
Silver Spring, United States
Karmanos
Detroit, United States
Minnesota Oncology Hematology
Minneapolis, United States
Memorial Sloane Kettering Cancer Center
New York, United States
Levine Cancer Institute
Charlotte, United States
MidLantic Urology
Bala-Cynwyd, United States
Keystone Urology Specialists
Lancaster, United States
Amarillo Urology Research
Amarillo, United States
Urology Clinics of North Texas
Dallas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
Virginia Oncology Associates
Fairfax, United States
Virginia Cancer Specialists
Norfolk, United States
University of Washington, Fred Hutchinson Cancer Center
Seattle, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Sydney Adventist Health
Wahroonga, Australia
Bendigo Health
Bendigo, Australia
Peninsula Health
Frankston, Australia
NEXT Oncology
Barcelona, Spain
Vall d'Hebron Institute of Oncology
Barcelona, Spain
NEXT Oncology
Madrid, Spain
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Trial contact
ORIC Clinical
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.